Accelerating the advancement of knowledge and the discovery of new, more effective cancer therapies
One in two Canadians is expected to develop cancer in their lifetime. One in four Canadians is expected to die from this disease. It is the leading cause of death in the country. Each year, cancer is responsible for 30% of all deaths in Canada.
IRIC was created in 2003 to fight the disease. The Institute stands out for its research model unique in the country, combining the complementary expertise of 28 Investigators with that of a research maturation team. IRIC can also rely on its 11 core facilities, including the country’s largest medicinal chemistry core facility in an academic setting.
A unique research model
A unique model that combines, under one roof, fundamental research activities, a university-level training program and a research maturation team.
The complementary expertise of 28 Investigators in fundamental, translational and applied research.
Innovative teaching methods to train the next generation of Investigators, particularly with its unique Master’s and Ph.D. in System Biology programs.
Privileged access to a research maturation hub specializing in drug discovery supported by the work of 40 chemists and biologists from the Medicinal Chemistry Core Facility.
Close collaborations between the clinical milieu and industry that have led, so far, to Phase I and Phase II clinical studies at the Jewish General Hospital, the Maisonneuve-Rosemont Hospital, the McMaster University Medical Centre, the Centre hospitalier de l’Université Laval and the University of British Columbia.
State-of-the-art infrastructures, including 11 core facilities, available to researchers from here and abroad.
For further information about IRIC activities,
History of IRIC
Construction of the Marcelle-Coutu Pavilion.
Robert Lacroix, Rector of the Université de Montréal, announces the creation of the Institute for Research in Immunology and Cancer in June 2003.
Creation of the Institute for Research in Immunology and Cancer by Pierre Chartrand, Chief Executive Officer, and arrival of the Institute’s first four recruits, Investigators Trang Hoang, Sylvain Meloche, Dr. Guy Sauvageau and Marc Therrien, at the Roger-Gaudry Pavilion. Dr. Guy Sauvageau is appointed Scientific Director of IRIC.
Opening of the Marcelle-Coutu Pavilion, and creation of the first core facilities.
Launch of the new Graduate Program in Molecular Biology, Systems Biology option.
Dr. Guy Sauvageau appointed Chief Executive Officer and renewal of his mandate as Scientific Director.
Creation of the first Canadian anticancer drug discovery chain in an academic setting. At the same time, the Institute creates its affiliate IRICoR, whose objective is the development and maturation of new therapies to fight cancer.
Kick-off of the first major IRIC fundraising campaign and of the IRIC Great Challenges Against Cancer Fund. The Institute receives a five million dollar donation from the Marcelle and Jean Coutu Foundation.
Inauguration of the Medicinal Chemistry Core Facility, led by Anne Marinier, which will enable the Institute to accelerate the development and commercialization of innovative anticancer drugs.
Marc Therrien appointed Scientific Director of IRIC.
Michel Bouvier appointed Chief Executive Officer of IRIC.
Renewal of Marc Therrien’s mandate as Scientific Director of IRIC.
Renewal of Michel Bouvier’s mandate as Chief Executive Officer of IRIC.